-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
-
-
-
-
-
-
-
Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
-
-
-
-
-
-
-
TD Cowen on Ocular Therapeutix (OCUL): 'Great Data Could Lead To 45% Upside Per Investor Survey'
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) PT Raised at RBC Capital; 'DR May Offer Additional Upside Potential'
-
-
-
-
-
-
-
Ocular Therapeutix hosts investor day detailing AXPAXLI trial progress
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) Misses Q2 EPS by 4c
-
-
-
-
-
-
-
William Blair Starts Ocular Therapeutix (OCUL) at Outperform, 'we believe Axpaxli has the potential to show best-in-class efficacy and durability'
-
413,562 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

